Skip to Content

AstraZeneca to Seek FDA Approval of COVID-19 Vaccine Within Weeks

MONDAY, March 8, 2021 -- AstraZeneca says it will file for emergency use authorization of its COVID-19 vaccine in the United States after it gets the results of a clinical trial within the next few weeks.

If the two-dose vaccine is approved by the U.S. Food and Drug administration, it would be the fourth COVID-19 vaccine available in the United States. Upon FDA approval, AstraZeneca plans "to deliver roughly 50 million doses instantly to Americans," Ruud Dobber, the company's executive vice president, told CBS News on Friday.

The AstraZeneca vaccine is already being used internationally, after being approved by the European Union, the United Kingdom, and the World Health Organization. The three currently approved vaccines in the United States are from Moderna and Pfizer -- both require two doses -- and a one-dose vaccine from Johnson & Johnson.

Dobber also told CBS News "we're very hopeful" that the AstraZeneca vaccine is "very effective against the U.K. variant" of the coronavirus, and that the company is "developing a potential new vaccine in case our current vaccine is not as effective as we were hoping for."

CBS News Article

© 2021 HealthDay. All rights reserved.

Read this next

SARS-CoV-2 Cardiac Involvement Low in Collegiate Athletes

TUESDAY, April 20, 2021 -- For U.S. collegiate athletes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a low prevalence of cardiac...

Total Vaccines, Measles Vaccines Down for Children During Pandemic

TUESDAY, April 20, 2021 -- During the pandemic, there has been a decrease in total and measles-containing vaccines in all children, according to a study published online April 15...

Some Supplements May Lower Risk for SARS-CoV-2 Positivity

TUESDAY, April 20, 2021 -- The use of probiotics, omega-3 fatty acids, multivitamins, and vitamin D supplements is associated with a reduction in the risk for testing positive for...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.